Pacira BioSciences, Inc. announced on October 16, 2024, the Board of Directors of the company appointed Shawn M. Cross to serve as the Chief Financial Officer of the Company, effective October 21, 2024. Mr. Cross will succeed Lauren Riker, who had been serving as interim Chief Financial Officer since October 1, 2024. Ms. Riker will continue to serve as the Company?s Senior Vice President of Finance and as principal accounting officer for Securities and Exchange Commission reporting purposes.

Mr. Cross, age 56, was most recently a member of the leadership team at Applied Molecular Transport, Inc., where he served as Chief Financial Officer from March 2020 to May 2022, President and Chief Operating Officer from May 2022 to March 2023, and as Chief Executive Officer and a director from March 2023 through the closing of its merger with Cyclo Therapeutics, Inc., in December 2023. Prior to his time at Applied Molecular Transport, Inc., Mr. Cross was an investment banker focused on the biopharmaceutical industry for over 20 years with both domestic and international experience having lived and worked in major financial centers including New York City, London, and San Francisco. He served as a Managing Director of Healthcare Investment Banking at JMP Securities, Inc. between September 2018 and February 2020 and previously held senior roles at Deutsche Bank Securities, Thomas Weisel Partners, and Wells Fargo Securities, LLC.

He began his investment banking career in the health care group at Alex. Brown & Sons. Mr. Cross also provided consulting services to companies in the biopharmaceutical industry between February 2024 and September 2024 and currently serves on the board of directors of Cyclo Therapeutics, Inc. He holds a B.S. in Kinesiology from the University of California, Los Angeles and an M.B.A. from Columbia Business School.